论文部分内容阅读
目的:观察益赛普联合柳氮磺吡啶治疗难治性强直性脊柱炎的临床效果。方法:选取2011年3月~2014年2月我院收治强直性脊柱炎患者66例,按数字法随机的分为观察组与对照组,每组各33例。其中对照组患者给予柳氮磺吡啶治疗,观察组患者给予益赛普联合柳氮磺吡啶治疗。观察两组患者治疗效果及各项实验室检查指标的变化。结果:经治疗后,观察组患者总有效率93.9%,对照组患者总有效率75.8%,观察组患者总有效率明显高于对照组,差异有统计学意义(P<0.050);观察组患者C反应蛋白、TNF-α、红细胞沉降率等指标均明显优于对照组,差异有统计学意义(P<0.05)。结论:益赛普联合柳氮磺吡啶能有效的提高难治性强直性脊柱炎的临床效果,改善各项实验室指标,临床效果确切,值得推广与应用。
Objective: To observe the clinical effect of Yi Sip combined with sulfasalazine in the treatment of refractory ankylosing spondylitis. Methods: 66 cases of ankylosing spondylitis in our hospital from March 2011 to February 2014 were randomly divided into observation group and control group according to the digital method, with 33 cases in each group. Patients in the control group were treated with sulfasalazine, and patients in the observation group were given sulfasalazine plus sulfasalazine. Observation of two groups of patients and the results of the laboratory test indicators change. Results: After treatment, the total effective rate was 93.9% in the observation group and 75.8% in the control group. The total effective rate in the observation group was significantly higher than that in the control group (P <0.050) C-reactive protein, TNF-α, erythrocyte sedimentation rate and other indicators were significantly better than the control group, the difference was statistically significant (P <0.05). Conclusion: Yipipu combined with sulfasalazine can effectively improve the clinical effect of refractory ankylosing spondylitis, improve the laboratory indicators, the clinical effect is exact and worthy of promotion and application.